797 related articles for article (PubMed ID: 25710471)
1. The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study.
Lie E; Kristensen LE; Forsblad-d'Elia H; Zverkova-Sandström T; Askling J; Jacobsson LT;
Ann Rheum Dis; 2015 Jun; 74(6):970-8. PubMed ID: 25710471
[TBL] [Abstract][Full Text] [Related]
2. Effect of Comedication With Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Retention of Tumor Necrosis Factor Inhibitors in Patients With Spondyloarthritis: A Prospective Cohort Study.
Sepriano A; Ramiro S; van der Heijde D; Ávila-Ribeiro P; Fonseca R; Borges J; Teixeira L; Carvalho PD; Cerqueira M; Neves J; Meirinhos T; Barcelos A; Sequeira G; Salvador MJ; Canas da Silva J; Santos H; Bernardes M; Vieira-Sousa E; Canhão H; Branco JC; Pimentel-Santos F; Landewé R
Arthritis Rheumatol; 2016 Nov; 68(11):2671-2679. PubMed ID: 27273894
[TBL] [Abstract][Full Text] [Related]
3. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
[TBL] [Abstract][Full Text] [Related]
4. The Effect of Comedication With a Conventional Synthetic Disease-Modifying Antirheumatic Drug on Drug Retention and Clinical Effectiveness of Anti-Tumor Necrosis Factor Therapy in Patients With Axial Spondyloarthritis.
Nissen MJ; Ciurea A; Bernhard J; Tamborrini G; Mueller R; Weiss B; Toniolo M; Exer P; Gabay C; Finckh A;
Arthritis Rheumatol; 2016 Sep; 68(9):2141-50. PubMed ID: 27015429
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register.
Lie E; van der Heijde D; Uhlig T; Mikkelsen K; Rødevand E; Koldingsnes W; Kaufmann C; Kvien TK
Ann Rheum Dis; 2011 Jan; 70(1):157-63. PubMed ID: 21062852
[TBL] [Abstract][Full Text] [Related]
6. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry.
Glintborg B; Østergaard M; Krogh NS; Tarp U; Manilo N; Loft AG; Hansen A; Schlemmer A; Fana V; Lindegaard HM; Nordin H; Rasmussen C; Ejstrup L; Jensen DV; Petersen PM; Hetland ML
Ann Rheum Dis; 2013 Jul; 72(7):1149-55. PubMed ID: 22941767
[TBL] [Abstract][Full Text] [Related]
7. The Ankylosing Spondylitis Disease Activity Score is a highly discriminatory measure of disease activity and efficacy following tumour necrosis factor-α inhibitor therapies in ankylosing spondylitis and undifferentiated spondyloarthropathies in China.
Xu M; Lin Z; Deng X; Li L; Wei Y; Liao Z; Li Q; Wei Q; Hu Z; Zhang Y; Lin Q; Huang J; Li T; Pan Y; Wu Y; Jin O; Yu B; Gu J
Rheumatology (Oxford); 2011 Aug; 50(8):1466-72. PubMed ID: 21441550
[TBL] [Abstract][Full Text] [Related]
8. Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register.
Kristensen LE; Karlsson JA; Englund M; Petersson IF; Saxne T; Geborek P
Arthritis Care Res (Hoboken); 2010 Oct; 62(10):1362-9. PubMed ID: 20506310
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register.
Chatzidionysiou K; Askling J; Eriksson J; Kristensen LE; van Vollenhoven R;
Ann Rheum Dis; 2015 May; 74(5):890-6. PubMed ID: 24431398
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration.
Lindström U; Di Giuseppe D; Delcoigne B; Glintborg B; Möller B; Ciurea A; Pombo-Suarez M; Sanchez-Piedra C; Eklund K; Relas H; Gudbjornsson B; Love TJ; Jones GT; Codreanu C; Ionescu R; Nekvindova L; Závada J; Atas N; Yolbas S; Fagerli KM; Michelsen B; Rotar Ž; Tomšič M; Iannone F; Santos MJ; Avila-Ribeiro P; Ørnbjerg LM; Østergaard M; Jacobsson LT; Askling J; Nissen MJ
Ann Rheum Dis; 2021 Nov; 80(11):1410-1418. PubMed ID: 34083206
[TBL] [Abstract][Full Text] [Related]
11. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
Heiberg MS; Koldingsnes W; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK
Arthritis Rheum; 2008 Feb; 59(2):234-40. PubMed ID: 18240258
[TBL] [Abstract][Full Text] [Related]
12. [Current therapy with TNFalpha blocking agents for ankylosing spondylitis and undifferentiated spondyloarthritis].
Brandt J; Sieper J; Braun J
Z Rheumatol; 2004 Jun; 63(3):203-10. PubMed ID: 15224223
[TBL] [Abstract][Full Text] [Related]
13. Conventional DMARDs in axial spondyloarthritis: wishful--rather than rational--thinking!
Landewé RB
Ann Rheum Dis; 2015 Jun; 74(6):951-3. PubMed ID: 25795908
[No Abstract] [Full Text] [Related]
14. Effectiveness and Drug Survival of TNF Inhibitors in the Treatment of Ankylosing Spondylitis: A Prospective Cohort Study.
Heinonen AV; Aaltonen KJ; Joensuu JT; Lähteenmäki JP; Pertovaara MI; Romu MK; Hirvonen HE; Similä AK; Blom ML; Nordström DC
J Rheumatol; 2015 Dec; 42(12):2339-46. PubMed ID: 26472421
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.
Callhoff J; Sieper J; Weiß A; Zink A; Listing J
Ann Rheum Dis; 2015 Jun; 74(6):1241-8. PubMed ID: 24718959
[TBL] [Abstract][Full Text] [Related]
16. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
17. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study.
Fagerli KM; Lie E; van der Heijde D; Heiberg MS; Lexberg AS; Rødevand E; Kalstad S; Mikkelsen K; Kvien TK
Ann Rheum Dis; 2014 Jan; 73(1):132-7. PubMed ID: 23291385
[TBL] [Abstract][Full Text] [Related]
18. The effect of extra-articular manifestations on tumor necrosis factor-α inhibitor treatment duration in patients with ankylosing spondylitis: nationwide data from the Korean College of Rheumatology BIOlogics (KOBIO) registry.
Kim Y; Park S; Kim HS
Clin Rheumatol; 2018 Dec; 37(12):3275-3284. PubMed ID: 30251059
[TBL] [Abstract][Full Text] [Related]
19. The use of TNF-inhibitors in ankylosing spondylitis in Austria from 2007 to 2009 - a retrospective analysis.
Nell-Duxneuner V; Schroeder Y; Reichardt B; Bucsics A
Int J Clin Pharmacol Ther; 2012 Dec; 50(12):867-72. PubMed ID: 23036238
[TBL] [Abstract][Full Text] [Related]
20. Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers.
Hellgren K; Dreyer L; Arkema EV; Glintborg B; Jacobsson LT; Kristensen LE; Feltelius N; Hetland ML; Askling J;
Ann Rheum Dis; 2017 Jan; 76(1):105-111. PubMed ID: 27147709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]